Medical Director
|
 |
Robert P. Schwartz
Medical Director/Senior Research Scientist
Degree: M.D., University of Padua, Italy
Phone: 410-837-3977 Ext. 276
Fax: 410-752-4218
Email:
rschwartz@friendsresearch.org |
Brief Biography
Dr. Schwartz is an addiction psychiatrist and former director of
the Division of Alcohol and Drug Abuse in the Department of
Psychiatry at the University of Maryland School of Medicine. His
research interests include entry and engagement in drug abuse
treatment, pharmacotherapy of opioid dependence, and health
services research. He is principal investigator of a National
Institute on Drug Abuse funded study examining personal,
community and program factors impacting upon drug abuse treatment
entry and is co-investigator on several other NIDA-funded
studies. These include studies of methadone treatment as a
re-entry strategy for heroin dependent prisoners, buprenorphine
for re-entering prisoners in Puerto Rico and role induction as a
means of engaging newly admitted patients treated with
buprenorphine. Dr. Schwartz serves as a co-investigator on
the Mid-Atlantic Clinical Trials Network and is a member of the
NIDA-F services research Initial Review Group.
Selected Publications
Schwartz, R.P., Highfield, D.A., Jaffe, J.H., Callaman, J.M.,
O’Grady, K.E., A randomized controlled trial of interim
methadone maintenance: 10 month-follow-up. Drug and Alcohol
Dependence, 86:30-36, 2007.
Schwartz, RP., McKenzie M., Rich J.D. Opioid addiction and
incarceration: an overview. Medicine and Health/Rhode Island,
90, 157-158, 2007.
Kinlock, T.W., Gordon M.S., Schwartz, R.P., O’Grady, K.E.,
Fitzgerald T.T., Wilson, M. A randomized clinical trial of
methadone maintenance for prisoners: Results at 1-month
post-release. Drug and Alcohol Dependence, 91(2-3):220-7.
2007.
Highfield, D.A., Schwartz R.P., Jaffe, J.H., Callaman J.,
O’Grady K.E. Intravenous and intranasal heroin dependent
treatment seekers: Similarities and differences. Addiction,102(11):1816-23,
2007.
Katz, E.C., Brown, B.S., Schwartz, R.P., King, S.D., Weintraub
E, Barksdale W. Impact of role induction on long-term drug
treatment outcomes. Journal of Addictive Diseases, 26, 81-90,
2007.
Albizu-Garcia, C., Caraballo Correa G., Hernandez Viver,
A.D.,Kinlock, T.W., Gordon, M.S., Antron Avila, C., Colón Reyes,
I., Schwartz R.P. Buprenorphine-Naloxone Treatment for
Pre-release Opioid Dependent Inmates in Puerto Rico.
Journal of Addiction Medicine,
1(6): 126-132, 2007.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A Study of
Methadone Maintenance for Male Prisoners: 3-Month Postrelease
Outcomes. Criminal Justice and Behavior 35, 34-47, 2007.
Schwartz RP, Kelly SM, O’Grady KE, Peterson JA, Reisinger HS,
Mitchell SG, Wilson ME, Brown BS. In-treatment v.
Out-of-treatment Opioid Dependent Adults: Drug Use and Criminal
History. Am J Drug and Alcohol Abuse 34(1), 17-28, 2008.
Peterson J, Schacht Reisinger HS, Schwartz RP, Mitchell SG,
Brown BS, Agar AH. (2008) Targeted Sampling in Drug Abuse
Research: A Review and Case Study. Field Methods,
20(2):155-170.
Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Peterson JA,
Reisinger HS, Agar MH, Brown BS. (2008) Attitudes toward
buprenorphine and methadone among opioid-dependent individuals.
American Journal on the Addictions,
17(5): 396 – 401.
Gordon MS, Kinlock TR, Schwartz RP, O’Grady KE. A Randomized
Clinical Trial of Methadone Maintenance for Prisoners: Findings
at 6-Months Post-Release. Addiction. 103(8):1333-42.
Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Agar
MH, Schwartz RP.
Incarceration and opioid withdrawal: The experiences of
methadone patients and out-of-treatment heroin users. Journal
of Psychoactive Substance Abuse. In Press.
Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM,
O’Grady KE, Marrari EA, Brown BS, Agar H. Premature Discharge
from Methadone Treatment: Patient Perspectives, Journal of
Psychoactive Substance Abuse. In Press.
Kelly SM, Schwartz RP, O’Grady KE, Mitchell SG, Reisinger HS,
Peterson JA, Agar MH, Brown BS, (2009) Gender differences
among in- and out-of-treatment opioid-addicted individuals.
Am J Drug and Alcohol Abuse, 35(1):38-42.
Katz EC, Schwartz RP, King SD, Highfield DA, O’Grady KE,
Billings T, Gandhi D, W Weintraub E, Glovinsky D, Barksdale W,
Brown BS.(2009) Brief v. extended buprenorphine detoxification
in a community treatment program: Engagement and Short-Term
Outcomes. Am J Drug and Alcohol Abuse, 35(2):63-7.
Peterson JA, Schwartz, RP, Mitchell SG, Reisinger HS, Kelly SM,
O’Grady KE, Brown BS, Agar MH. Why don’t out-of-treatment
individuals enter methadone treatment programs? International
J Drug Policy, In Press.
Schwartz RP, Jaffe JH, O’Grady KE, Kinlock TW, Gordon MS, Kelly
SM, Wilson ME, Ahmed A. Interim Methadone Treatment: Impact on
Arrests. Drug and Alcohol Dependence, In Press.
Mitchell SG, Kelly SM, Barry BS, Reisinger HS, Peterson JA, Ruhf
A, Agar MH, O’Grady KE, Schwartz RP Uses of diverted methadone
and buprenorphine by opioid-addicted individuals in Baltimore,
Maryland, American Journal on Addictions, In Press.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A
Randomized Clinical Trial of Methadone Maintenance for
Prisoners: Results at Twelve-Months Post-Release, Journal of
Substance Abuse Treatment. In Press. |